Institute of Immunology, Hannover Medical School, Hannover, Germany.
Arch Immunol Ther Exp (Warsz). 2012 Jun;60(3):183-90. doi: 10.1007/s00005-012-0172-3. Epub 2012 Apr 5.
Graft-versus-host disease (GvHD) remains a major complication after allogeneic hematopoietic stem-cell-transplantation. Present GvHD prophylaxis and treatment is still based on unspecific immunosuppressive drug therapy. Over the last decade, the potential of cell-based therapies involving the infusion of regulatory T cells has emerged as a feasible alternative approach for the treatment and prevention of GvHD. Here we review current efforts to translate data obtained in rodent models into clinical trials. Special emphasis is placed on the variety of strategies to generate sufficient numbers of alloantigen-specific regulatory T cells for adoptive cell therapy. This can be achieved either by expansion or by induction of a regulatory phenotype in naive T cells. Stability of the immunosuppressive phenotype of transferred regulatory T cells even in the highly inflammatory environment of acute GvHD will be thereby a critical parameter for actual therapeutic application.
移植物抗宿主病（GvHD）仍然是异基因造血干细胞移植后的主要并发症。目前的 GvHD 预防和治疗仍然基于非特异性免疫抑制药物治疗。在过去的十年中，涉及输注调节性 T 细胞的细胞治疗的潜力已经成为治疗和预防 GvHD 的可行替代方法。在这里，我们回顾了将啮齿动物模型中获得的数据转化为临床试验的当前努力。特别强调了产生足够数量的同种抗原特异性调节性 T 细胞用于过继细胞治疗的各种策略。这可以通过扩增或在幼稚 T 细胞中诱导调节表型来实现。转移的调节性 T 细胞的免疫抑制表型的稳定性，即使在急性 GvHD 的高度炎症环境中，也将是实际治疗应用的一个关键参数。
